Cas:143157-25-9 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose manufacturer & supplier

Chemical Name:3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose

CAS.NO:143157-25-9

Synonyms:3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose

Molecular Formula:C₁₉H₁₆F₂O₆

Molecular Weight:378.32400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:495.925ºC at 760 mmHg

Density:1.412 g/cm3

Index of Refraction:

PSA:82.06000

Exact Mass:378.09100

LogP:2.42150

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose Use and application,3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose technical grade,usp/ep/jp grade.

Related News: The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose manufacturer The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose supplier The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 3,5-Di-O-benzoyl-2-deoxy-2,2-difluoro-D-erythro-pentofuranose factory Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.